-MSH reduced leukocytes, mast cells, and fibroblasts at 3 and 7 days post-injury, while also decreasing scar area and improving collagen fiber organization at days 40 and 60, indicating its potential to promote a more regenerative wound healing pathway in the studied model
PLoS biology
ng kn np sau khi s dng
Transport of various molecules via adsorption can be carried out by caveolar or clathrin-coated membranes
It is indicated for the treatment of adult patients with R/R LBCL after two or more lines of systemic therapy, including DLBCL, HGBCL, and PMBCL ( Abecma, the first anti-BCMA CAR-T product, was approved on March 26, 2021, and is indicated for treating adult patients with R/R MM after immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and monoclonal antibodies targeting CD38 ( Carvykti, a bi-epitope nanobody-based anti-BCMA CAR-T product, was approved on February 28, 2022, for adults with R/R MM after four or more prior lines of therapy, including IMiDs, PIs, and an anti-CD38 monoclonal antibody ( Aucatzyla, a CD19-directed CAR-T therapy, received approval on November 8, 2024, for treating adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL)
